04 / What the cited FDA pages settle
Wolverine legal status: BPC-157 TB-500 access is unclear.
Sponsors withdrew requests for BPC-157 and TB-500, so the names left Category 2, an FDA safety warning group. That removal wasn't approval. The sources give no result from the 2026 meeting, so they don't settle what a pharmacy may do for you now.
The meeting date passed, but these sources give no result
The cited FDA calendar said BPC-157 and TB-500 were under review in 2026. It listed a July 23-24, 2026 meeting [13]. The question was whether some state-licensed pharmacies might use these raw ingredients for one patient.
Those dates have passed, yet the sources listed here don't say what happened afterward. The meeting could only give advice; the FDA must make any later rule [14]. You can't read an outcome into the old calendar.
Here’s what matters if you're asking about access. The calendar doesn't approve a drug or let a pharmacy fill your prescription. I’d have the pharmacy point to today's rule before I relied on access.
This page gives broad legal facts about BPC-157 TB-500. It can't decide whether a sale or prescription is lawful for you. Nothing here offers either substance. Your own pharmacy must answer your case.
BPC-157 and TB-500 left FDA safety group Category 2
Federal law treats two kinds of pharmacy differently, including when they handle BPC-157 and TB-500. A state-licensed pharmacy may make medicine for one named person. A separate FDA-registered facility may make larger batches for clinics [14]. Neither kind may use every raw ingredient.
For a state-licensed pharmacy, a raw ingredient needs one of three grounds [14]. A standard book used by pharmacists may list it. An FDA-approved drug may already contain it. Or the FDA may put it on an allowed list. The cited pages show none of those grounds for BPC-157 or TB-500.
On September 29, 2023, the FDA put BPC-157 in Category 2, its safety warning group for raw ingredients with serious possible risks [12]. The agency warned about possible immune trouble. It also questioned whether the ingredient would have the stated contents and purity.
That FDA update placed the TB-500 section of Thymosin Beta-4 in Category 2 [12]. Thymosin Beta-4 is a larger body protein, while TB-500 copies only one short section. The FDA raised possible immune trouble and missing safety facts.
Sponsors had asked the FDA to consider allowing these raw ingredients for made-to-order medicine. The cited page doesn't name those sponsors, and they later withdrew both requests. On April 22, 2026, the safety worries still appeared beside both names [12]. Withdrawal didn't approve either substance or your mixed vial.
The 2026 calendar didn't make either substance legal
Sponsors withdrew the BPC-157 and TB-500 requests. On the FDA page dated April 22, 2026, neither name appears in Category 2, the agency's safety warning group [12]. Leaving that group didn't mean either substance was approved or allowed for you.
The FDA calendar named two chemical forms of BPC-157. Free base means the ingredient stands alone, while acetate means it is joined to an acid. The calendar named the same two forms of TB-500. The cited page doesn't say that any form works better or is safer.
All four BPC-157 and TB-500 entries were set for the July 23-24, 2026 meeting about raw ingredients in medicine made for one person [13]. BPC-157 and TB-500 had entered Category 2 in 2023 [12]. Both were due for review in 2026 [13]. Neither had a special exception.
That meeting was one step in the FDA process, not a new rule [14]. The sources used here give no meeting result. A prescription alone can't change the raw-ingredient rule. Your doctor or pharmacist needs a newer FDA answer before saying access is settled.
A pharmacy-made drug starts with one named patient
A doctor or other licensed health worker first examines you [14]. If made-to-order medicine fits your care, that person may write a prescription. The visit can happen in an office or by a legal video call.
If the raw ingredient is allowed, the health worker puts your name on the prescription [14]. A state-licensed pharmacy may then prepare medicine for you. A separate FDA-registered facility may make larger batches for clinics [14].
Your name on a prescription isn't enough by itself. The pharmacy still must show that today's rule allows the raw ingredient [14]. A video call can't change that rule.
The cited pages don't give a clear day-to-day answer for BPC-157 or TB-500. That is why the 2026 FDA review mattered [13]. This page can't direct you to a supplier. Your doctor and pharmacist need a current answer for your case.
These sources don’t give today’s final access answer
The answers below state what the cited FDA pages say. Those pages don't include the past meeting's result. Your pharmacy must follow today's rule. Ask your pharmacist to name the rule used for you.
Is the Wolverine blend legal?
The Wolverine mixture isn't an FDA-approved drug. Neither BPC-157 nor TB-500 has approval for human use. Sponsors asked the FDA to consider the raw ingredients for made-to-order medicine, then withdrew those requests. On April 22, 2026, neither name remained in Category 2, the agency's safety warning group [12]. Leaving the group wasn't approval. A pharmacist must use today's rule to answer for your prescription.
Can a pharmacy make BPC-157 for one patient?
A pharmacy with a state license may prepare medicine for one named person, but only when a licensed health worker writes a prescription and the federal rule allows the raw ingredient. The FDA put BPC-157 in Category 2, its safety warning group, on September 29, 2023. The April 22, 2026 page says the BPC-157 sponsor withdrew its request but doesn't tell pharmacies what followed [12]. A separate FDA-registered facility may make larger batches [14]. Your pharmacy must explain which current rule allows BPC-157 for you.
What has the FDA said about Wolverine access now?
The FDA page dated April 22, 2026 says sponsors withdrew both requests. Neither substance remains in Category 2, its safety warning group. On September 29, 2023, the agency had put BPC-157 and the TB-500 section of Thymosin Beta-4, a larger body protein, in Category 2 [12]. A July 23-24, 2026 meeting was scheduled to examine raw ingredients for made-to-order medicine [13]. The cited sources don't give the result. Your pharmacy still needs a current rule for your prescription.